TrueBinding Receives FDA IND Go Ahead for Parkinsons Phase 2A Clinical Trial
November 18, 2024 17:35 ET | Source: TrueBinding Inc. FOSTER CITY, Calif.,…
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the…
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue…
CORRECTING and REPLACING Mevion Delivers Wisconsin’s First Compact Proton Therapy System to the Froedtert & the Medical College of Wisconsin Clinical Cancer Center
LITTLETON, Mass. & MILWAUKEE--(BUSINESS WIRE)--#MevionFIT--Please replace the release with the following corrected…
Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
SBS-1000 was shown to be safe and well tolerated in healthy volunteers…
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company…
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation…
A2 Bio Highlights Progress of Tmod CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Oral presentation provides update on enhancements to improve participant diversity and enrollment…